Find a study

📍 Southern Arizona VA Health Care System, Tucson, AZ · Tucson, AZ · +23 more US sites · Get directions →

Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions).

📍 Banner Sun Health Research Institute · Sun City, AZ · +39 more US sites · Get directions →

The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.

📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

📍 Banner Sun Health Research Institute · Sun City, AZ · +32 more US sites · Get directions →

Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

📍 University of Alabama Birmingham · Birmingham, AL · +39 more US sites · Get directions →

Development of a central repository for PD-related genomic data for future research.

📍 Site 200 · Phoenix, AZ · +39 more US sites · Get directions →

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

📍 Northern Arizona Healthcare · Flagstaff, AZ · +34 more US sites · Get directions →

This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol.

📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.

📍 Mayo Clinic · Phoenix, AZ · +33 more US sites · Get directions →

The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

📍 Rehabilitation & Neurological Services /ID# 248517 · Huntsville, AL · +39 more US sites · Get directions →

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.

📍 The Belinga Clinic · Fort Smith, AR · +39 more US sites · Get directions →

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.

📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.

📍 University of Alabama at Birmingham · Birmingham, AL · +29 more US sites · Get directions →

The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

📍 TrialSphere Corp, Merz Investigational Site #0010513 · Chandler, AZ · +39 more US sites · Get directions →

In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections.

📍 University of Alabama at Birmingham · Birmingham, AL · +33 more US sites · Get directions →

The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel.

📍 Mayo Clinic Hospital · Phoenix, AZ · +31 more US sites · Get directions →

The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.

📍 Sunnybrook Health Sciences Centre · Toronto, Ontario · Get directions →

Obstructive sleep apnea (OSA), which causes abnormal pauses in breathing during sleep, is common in patients with vascular cognitive impairment (VCI) and Alzheimer's disease (AD), and exacerbates the cognitive deficits seen in these conditions. OSA is typically treated with continuous positive airway pressure (CPAP), which has been shown to improve cognition in VCI and slow cognitive decline in AD.

📍 TrialSphere Corp, Merz Investigational Site #0010513 · Chandler, AZ · +39 more US sites · Get directions →

In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections.

📍 University of Alabama at Birmingham · Birmingham, AL · +23 more US sites · Get directions →

This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week.

📍 Sunybrook Research Institute · Toronto, Ontario · Get directions →

The goal of this study is to establish safety and feasibility of intracerebral delivery of GCase via MRgFUS. This technique may offer potential benefits given the exposure of the putamen to GCase in animal models has been shown to be efficacious in improving Parkinson's disease pathology and phenotype.

📍 Lighthouse Psychiatry · Gilbert, AZ · +26 more US sites · Get directions →

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

📍 Banner Alzheimer's Institute (BAI)-Phoenix · Phoenix, AZ · +25 more US sites · Get directions →

This is an observational study in which data are collected and studied from Parkinson's disease patients who have movement symptoms despite taking standard Parkinson's medications. In observational studies, observations are made without any changes to the participant's healthcare or treatment plan.

📍 University of Arkansas for Medical Sciences · Little Rock, AR · +24 more US sites · Get directions →

This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.

📍 University of Alabama at Birmingham - Dept. of Psychiatry · Birmingham, AL · +23 more US sites · Get directions →

The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.

📍 University of Aizona Health Sciences · Tucson, AZ · +22 more US sites · Get directions →

The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.

📍 Rehabilitation and Neurological Services /ID# 270782 · Huntsville, AL · +30 more US sites · Get directions →

Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.

📍 Mayo Clinic in Rochester · Rochester, MN · Get directions →

This study is testing a new brain stimulation treatment called theta burst stimulation (TBS) to see if it can reduce suicidal thoughts in teens with major depressive disorder (MDD). Participants will be followed for 10 days for symptom changes and for 1 year for longer-term outcomes.

📍 GSK Investigational Site · Arcadia, CA · +39 more US sites · Get directions →

This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

📍 Neurology and Pain Specialty · Aliso Viejo, CA · +27 more US sites · Get directions →

The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.

📍 Yale-New Haven Children's Hospital - PIN · New Haven, CT · +21 more US sites · Get directions →

To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.

📍 Xenoscience Inc · Phoenix, AZ · +26 more US sites · Get directions →

The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue.

📍 Noble Clinical Research · Tucson, AZ · +33 more US sites · Get directions →

This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo.

📍 University of Alabama at Birmingham · Huntsville, AL · +24 more US sites · Get directions →

This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

📍 Scottsdale Research Institute · Phoenix, AZ · +38 more US sites · Get directions →

The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.

📍 Central Research Associates /ID# 260161 · Birmingham, AL · +39 more US sites · Get directions →

A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.

📍 Harmonex /ID# 277517 · Dothan, AL · +32 more US sites · Get directions →

Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains.

📍 Barrow Neurological Institute · Phoenix, AZ · +26 more US sites · Get directions →

The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

📍 Neurocrine Clinical Site · Bryant, AR · +21 more US sites · Get directions →

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

📍 University of Alabama at Birmingham Children's of Alabama · Birmingham, AL · +14 more US sites · Get directions →

This comparative effectiveness study will clarify current first-line preventive treatment approaches for use by neurologists, psychologists, and primary care providers in the context of real world care, and will demonstrate the feasibility of Cognitive Behavioral Therapy (CBT) via telehealth for youth with migraine. The focus is on applying evidence-based care and enhancing access to it.

📍 Harmonex Neuroscience Research · Dothan, AL · +39 more US sites · Get directions →

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

📍 IMA Clinical Research Phoenix · Phoenix, AZ · +39 more US sites · Get directions →

X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

📍 UAB Psychiatry and Behavioral Neurology · Birmingham, AL · +32 more US sites · Get directions →

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

📍 Accellacare - Moorpark · Moorpark, CA · +31 more US sites · Get directions →

This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a treatment period that will last a minimum of 12 months, and the follow up period that will last approximately 2 months.

📍 Harmonex Neuroscience Research · Dothan, AL · +33 more US sites · Get directions →

X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

📍 Site 7074 · Birmingham, AL · +37 more US sites · Get directions →

The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.

📍 Alabama CRS · Birmingham, AL · +24 more US sites · Get directions →

A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes.

📍 Neurocrine Clinical Site · Huntsville, AL · +39 more US sites · Get directions →

This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

📍 Clinical Research Site · Bellflower, CA · +39 more US sites · Get directions →

This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

📍 Arizona Liver Health · Chandler, AZ · +39 more US sites · Get directions →

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.

📍 Draig Clinical Site · Bentonville, AR · +22 more US sites · Get directions →

The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo.

📍 GSK Investigational Site · Chandler, AZ · +29 more US sites · Get directions →

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

📍 NoesisPharma, LLC · Phoenix, AZ · +31 more US sites · Get directions →

The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel.

📍 Arizona Liver Health - Chandler · Chandler, AZ · +30 more US sites · Get directions →

Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also asse

📍 Noble Clinical Research · Tucson, AZ · +27 more US sites · Get directions →

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).

📍 Site 6036 · Chandler, AZ · +26 more US sites · Get directions →

The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer and/or atypical antipsychotic, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.

📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.

📍 Yale University School of Medicine · New Haven, CT · +19 more US sites · Get directions →

The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.

📍 Ki Health Partners LLC DBA New England Institute for Clinical Research · Stamford, CT · +14 more US sites · Get directions →

The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.

📍 Vanda Investigational Site · Phoenix, AZ · +20 more US sites · Get directions →

The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder

📍 University of Alabama at Birmingham · Birmingham, AL · +20 more US sites · Get directions →

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression?